Literature DB >> 8500862

Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs.

C M Erley1, U Haefele, N Heyne, N Braun, T Risler.   

Abstract

The effects of four different antihypertensive drugs (the Ca(2+)-channel blocker felodipine, the beta-blocker metoprolol, the angiotensin converting enzyme inhibitor ramipril, and the alpha-blocking agent doxazosin) on microalbuminuria and renal hemodynamics were evaluated in a double-blind, crossover study in 17 patients (10 women, seven men, aged 39 +/- 14 years) with mild-to-moderate essential arterial hypertension and microalbuminuria. Patients were studied after a 2-week placebo phase preceded by 2 weeks off all medication and after 12 weeks of treatment with each drug. Between each drug treatment, there was another 14-day placebo washout period. At the end of the study, we performed two additional 2-week placebo periods. After each placebo and treatment period, we measured albumin excretion during a 3-day collecting period. Renal hemodynamics were assessed by clearance techniques (inulin and p-aminohippurate clearance) at the end of the first and last placebo periods and after each treatment period. All drugs reduced mean arterial pressure and microalbuminuria to a similar and statistically significant (p < 0.05) extent (mean arterial pressure: placebo phase, 116 +/- 5 mm Hg; felodipine, 101 +/- 4 mm Hg; metoprolol, 101 +/- 5 mm Hg; ramipril, 101 +/- 4 mm Hg; doxazosin, 102 +/- 5 mm Hg; urinary albumin excretion: placebo phase, 46 +/- 50 mg/day; felodipine, 18 +/- 23 mg/day; metoprolol, 14 +/- 12 mg/day; ramipril, 16 +/- 16 mg/day; doxazosin, 14 +/- 14 mg/day). Mean arterial pressure levels and urinary albumin excretion returned to baseline after the last placebo period (110 +/- 6 mm Hg and 40 +/- 46 mg/day, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500862     DOI: 10.1161/01.hyp.21.6.810

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

1.  The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population.

Authors:  Taco B M Monster; Wilbert M T Janssen; Paul E de Jong; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 2.  Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.

Authors:  Christine R Culy; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Treatment of patients with essential hypertension and microalbuminuria.

Authors:  J Redon
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 4.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 5.  Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension.

Authors:  M Haria; G L Plosker; A Markham
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

Review 6.  Microalbuminuria in hypertension.

Authors:  Paolo Palatini
Journal:  Curr Hypertens Rep       Date:  2003-06       Impact factor: 5.369

Review 7.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

Review 8.  Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.

Authors:  B Fulton; A J Wagstaff; E M Sorkin
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 9.  Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.

Authors:  J E Frampton; D H Peters
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

Review 10.  Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.

Authors:  M Archer; N Dogra; Z Dovey; T Ganta; H-S Jang; J A Khusid; A Lantz; M Mihalopoulos; J A Stockert; A Zahalka; L Björnebo; S Gaglani; M R Noh; S A Kaplan; R Mehrazin; K K Badani; P Wiklund; K Tsao; D J Lundon; N Mohamed; F Lucien; B Padanilam; M Gupta; A K Tewari; N Kyprianou
Journal:  Cell Commun Signal       Date:  2021-07-20       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.